Podcast
MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson
Mastering the Medical Affairs Professional Role: Inside and Out
Summary
In this episode, Tom Caravela welcomes Kent Christofferson to discuss his career journey and insights into the MSL role. Kent shares his transition from academia to industry, highlighting the importance of mastering the MSL role and thinking like a Key Opinion Leader (KOL). He delves into the value proposition of MSLs, the significance of team effectiveness, and the challenges of handling multiple roles. The conversation covers compliance, technology, and future medical affairs directions, emphasizing digital engagement and the shift towards relationship-based interactions. Kent concludes with strategies for effective KOL engagement and the importance of leadership support in the evolving MSL landscape.
Kent Christopherson, Senior Director, Medical Affairs at Orchard Therapeutics discusses the art of Mastering the Medical Affairs Professional Role Internally and Externally.
Kent shares…
π Why MSLs need to “think like a KOL”
π The importance of Individual Development Plans
π Integrated Team Effectiveness Model- (ITEM) ref: 2006, Louise Lemieux-Charles, Wendy L McGuire
π Why clinical insights is the currency for MSL value internally
π Why it is vital to understand what KOLs motivation is in order to ensure value and meet deliverables
Medical Science Liaison, Key Opinion Leader, MSL Career Transition, Medical Affairs Strategies, Effective KOL Engagement
Related Topics
You May Also Like
MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson
Podcast
MSL Talk: Tom Caravela
Over-Negotiation-How to Botch a Job Offer
Article
S.F. Oosting, J. Barriuso, A. Bottomley, M. Galotti, B. Gyawali, B. Kiesewetter, N.J. Latino, F. Martinelli, M. Pe, G. Pentheroudakis, F. Roitberg, H. Vachon, E.G.E. de Vries, M. Piccart, N.I. Cherny
Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale
Article
Dylan V Neel, David S Shulman, Clement Ma, Florence Bourgeois, Steven G DuBois
Sponsorship of oncology clinical trials in the United States according to age of eligibility
Article
Michael Z. Liao, Dan Lu, Matts KΓ₯gedal, Dale Miles, Divya Samineni, Stephanie N. Liu, Chunze Li
Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?
Article
Karen Geary